Bentivoglio, Anna Rita
 Distribuzione geografica
Continente #
NA - Nord America 17.987
EU - Europa 11.055
AS - Asia 10.505
SA - Sud America 2.044
Continente sconosciuto - Info sul continente non disponibili 505
AF - Africa 298
OC - Oceania 36
Totale 42.430
Nazione #
US - Stati Uniti d'America 17.351
SG - Singapore 4.424
DE - Germania 3.012
CN - Cina 2.479
IT - Italia 2.230
BR - Brasile 1.600
SE - Svezia 1.371
VN - Vietnam 1.178
FR - Francia 1.072
UA - Ucraina 877
GB - Regno Unito 586
IE - Irlanda 493
IN - India 403
FI - Finlandia 340
HK - Hong Kong 339
ID - Indonesia 316
RU - Federazione Russa 311
CA - Canada 290
JP - Giappone 284
TR - Turchia 204
BD - Bangladesh 189
AR - Argentina 155
NL - Olanda 146
PL - Polonia 133
MX - Messico 127
IQ - Iraq 110
ES - Italia 106
EC - Ecuador 77
BE - Belgio 75
KR - Corea 71
ZA - Sudafrica 71
CI - Costa d'Avorio 70
AT - Austria 67
PK - Pakistan 60
SA - Arabia Saudita 59
CO - Colombia 54
VE - Venezuela 54
IR - Iran 46
PH - Filippine 46
UZ - Uzbekistan 40
IL - Israele 35
AU - Australia 32
CL - Cile 31
JM - Giamaica 30
LT - Lituania 30
CR - Costa Rica 29
JO - Giordania 28
TT - Trinidad e Tobago 28
CH - Svizzera 27
MA - Marocco 27
PY - Paraguay 26
KE - Kenya 25
CZ - Repubblica Ceca 24
HN - Honduras 21
KZ - Kazakistan 21
MY - Malesia 21
RO - Romania 20
AE - Emirati Arabi Uniti 19
AZ - Azerbaigian 19
BO - Bolivia 19
NI - Nicaragua 19
TN - Tunisia 18
GT - Guatemala 17
EG - Egitto 16
PE - Perù 15
PR - Porto Rico 15
BG - Bulgaria 14
DZ - Algeria 14
EE - Estonia 14
SV - El Salvador 14
DK - Danimarca 13
AL - Albania 12
EU - Europa 12
HU - Ungheria 12
NP - Nepal 12
TH - Thailandia 12
UY - Uruguay 12
ET - Etiopia 11
LB - Libano 11
OM - Oman 11
PA - Panama 11
PT - Portogallo 10
SN - Senegal 10
GR - Grecia 9
PS - Palestinian Territory 9
TW - Taiwan 9
CW - ???statistics.table.value.countryCode.CW??? 8
BB - Barbados 7
BY - Bielorussia 7
DO - Repubblica Dominicana 7
MD - Moldavia 7
GP - Guadalupe 6
KG - Kirghizistan 6
LU - Lussemburgo 6
NO - Norvegia 6
RS - Serbia 6
SC - Seychelles 6
AM - Armenia 5
KH - Cambogia 5
KW - Kuwait 5
Totale 41.847
Città #
Singapore 2.299
Ashburn 2.173
San Jose 1.758
Chandler 1.541
Jacksonville 481
Dublin 480
Beijing 450
Milan 424
Ho Chi Minh City 379
San Mateo 369
Los Angeles 364
Council Bluffs 349
New York 348
Rome 340
Hanoi 311
Nanjing 294
Jakarta 279
Ann Arbor 275
Lauterbourg 271
Wilmington 257
Tokyo 244
Hefei 241
Munich 221
Dallas 220
Hong Kong 204
Boston 199
Dearborn 188
Frankfurt am Main 172
Houston 162
Chicago 155
The Dalles 154
Woodbridge 154
Santa Clara 144
Lawrence 141
São Paulo 140
Nürnberg 137
Moscow 135
Cattolica 126
Marseille 119
Seattle 118
Izmir 117
Boardman 116
North Bergen 106
Lancaster 103
Redwood City 102
Warsaw 98
Helsinki 95
Princeton 95
Buffalo 91
Atlanta 89
Nanchang 89
Phoenix 89
Redmond 89
Brooklyn 86
Fairfield 83
Figino 80
Shenyang 74
London 71
Abidjan 70
Da Nang 69
Norwalk 69
Brussels 68
Kent 62
Cambridge 60
Hebei 59
Montreal 59
Orem 57
Denver 56
Jiaxing 56
Rio de Janeiro 56
Mountain View 55
Toronto 55
Hangzhou 54
Tianjin 54
Naples 53
Pune 53
Shanghai 53
Seoul 51
University Park 51
Nuremberg 49
Haiphong 48
Memphis 48
Changsha 47
Paris 47
St Louis 46
Brasília 44
Bremen 44
Guangzhou 44
Amsterdam 43
Kunming 43
Carrboro 41
Chennai 41
Lappeenranta 41
San Francisco 41
Johannesburg 40
Turin 39
Leawood 38
Philadelphia 38
Vienna 38
Baghdad 37
Totale 20.606
Nome #
Frameless stereotaxy in subthalamic deep brain stimulation: 3-year clinical outcome 1.271
Effects of stimulation of the subthalamic nucleus on naming and reading nouns and verbs in Parkinson's disease 380
Measuring gait quality in Parkinson’s disease through real-time gait phase recognition 335
What about the caregiver? A journey into Parkinson's disease following the burden tracks 285
The role of small intestinal bacterial overgrowth in Parkinson's disease 271
Clinical and genetic characteristics of late-onset Huntington's disease 268
Reduced Cancer Incidence in Huntington's Disease: Analysis in the Registry Study 258
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 253
F057 Affective and cognitive components of theory of mind in Huntington’s disease: yoni task performance in early and mid-disease stages 249
Heart Rate Variability during wake and sleep in Huntington's Disease patients. An observational, cross-sectional, cohort study 249
Social cognition in basal ganglia pathologies: Theory of Mind in Huntington's and Parkinson's diseases 247
Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants 246
Unilateral Extradural Motor Cortex Stimulation is Safe and Improves Parkinson's Disease at 1 Year 235
Difference in striatal dopamine transporter availability and psychiatric symptoms in Parkinson's disease subtypes: 123I-FP-CIT SPECT results 234
Beyond the CAG triplet number: exploring potential predictors of delayed age of onset in Huntington's disease 229
Striatal dopamine transporter (DAT) availability and affective symptoms in movement disorders: a 123I-FP-CIT SPECT study. 227
Patient's Loss of Empathy Is Associated With Caregiver Burden 227
Botulinum toxin A versus B in sialorrhea: A prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease. 224
Assessment of neurological manifestations in hospitalized patients with COVID-19 220
Cognitive outcome 5 years after bilateral chronic stimulation of subthalamic nucleus in patients with Parkinson's disease 216
Association of depressive symptoms with circadian blood pressure alterations in Parkinson's disease 216
PUNDING IN PARKINSON'S DISEASE: THE IMPACT OF PATIANT'S AWARENESS ON DIAGNOSIS 213
RAB32 mutation in Parkinson's disease [2] 210
Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease 210
Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a (123)I-FP-CIT SPECT study 208
Extradural motor cortex stimulation improves gait, speech, and language in a patient with pure akinesia 207
Rehabilitation of hypomimia in Parkinson's disease: a feasibility study of two different approaches 204
Neuroacanthocytosis Syndromes in an Italian Cohort: Clinical Spectrum, High Genetic Variability and Muscle Involvement 204
Frequency and phenotypes of LRRK2 G2019S mutation in Italian patients with Parkinson's disease 201
Correlations Between Striatal Dopamine Transporter (DAT) Availability and Psychiatric Symptoms in Movement Disorders: A 123I-FP-CIT SPECT Study. 200
Mutation screening of the DYT6/THAP1 gene in Italy 200
Chronic motor cortex stimulation in patients with advanced Parkinson's disease and effects on striatal dopaminergic transmission as assessed by 123I-FP-CIT SPECT: a preliminary report. 200
Phenotypic characterisation of DYT13 primary torsion distonia. 196
The left parietal lobe plays a role in the pathogenesis of blepharospasm? 196
An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients 196
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 194
Analysis of blink rate in patients with blepharospasm 190
Olfactory dysfunction in Parkinsonism caused by PINK1 mutations 189
Atrofia multisistemica: correlazioni tra caratteristiche cliniche, prove di reflettività cardiovascolare e reperti di risonanza magnetica 186
Effects of bilateral subthalamic nucleus stimulation and medication on parkinsonian speech impairment 186
Emotional Awareness, Relationship Quality, and Satisfaction in Patients With Parkinson's Disease and Their Spousal Caregivers 186
Effects of COVID-19 Lockdown on Movement Disorders Patients With Deep Brain Stimulation: A Multicenter Survey 186
Age at onset and symptom spread in primary adult-onset blepharospasm and cervical dystonia 184
The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life 182
Extradural Motor Cortex Stimulation might improve episodic and working memory in patients with Parkinson’s disease 182
Prevalence of spinocellulart ataxia type 2 mutation among ittalian Parkinsonian patients 181
Anhedonia in Parkinson's disease patients with and without pathological gambling: A case-control study 180
Movement disorders in multiple sclerosis: Causal or coincidental association? 179
Prevalence of Impulsive-Compulsive Symptoms in Elderly Parkinson's Disease Patients: A Case-Control Study 179
Extradural Motor Cortex Stimulation in Parkinson's Disease: Long-Term Clinical Outcome. 179
Reliability of Clinical Diagnosis of Dystonia 177
Movement disorders following mechanical thrombectomy resulting in ischemic lesions of the basal ganglia: An emerging clinical entity 176
New olfactometric findings in Parkinson's disease 176
Wake and Sleep EEG in Patients With Huntington Disease: An eLORETA Study and Review of the Literature 175
Dopaminergic agents and nutritional status in Parkinson's disease 174
Botulinum toxin in the treatment of outlet obstruction constipation due to puborectalis syndrome 172
Mitochondrial Signatures in Circulating Extracellular Vesicles of Older Adults with Parkinson's Disease: Results from the EXosomes in PArkiNson's Disease (EXPAND) Study 171
Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs 170
Depression Symptoms and Clinical Subtypes in Parkinson's Disease Patients: a I-123-FP-CIT SPECT Study 170
Use of ACE-inhibitors and falls in patients with Parkinson's disease 170
Effect of aging on biomarkers and clinical profile in Parkinson's disease 169
Novel mutations in SPG11 cause hereditary spastic paraplegia associated with early-onset levodopa responsive parkinsonism 168
Non-DYT1 early onset primary torsion dystonia: comparison with DYT1 phenotype and review of the literature 167
Nigro-striatal involvement in primary progressive freezing gait: insights into a heterogeneous pathogenesis 166
Dystonia gravidarum: a new case with a long follow-up 166
Aceruloplasminemia: a novel mutation in a family with marked phenotypic variability 166
Parkinson’s disease and virtual reality rehabilitation: cognitive reserve influences the walking and balance outcome 166
Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia. Results of a randomised, placebo-controlled study. 165
A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. 165
Botulinum Toxin A and B in sialorrhea: Long-term data and literature overview 165
Impulsive-compulsive behaviors in parkin-associated Parkinson disease 165
Ataxia-Telangiectasia Presenting as Tremor-Predominant Syndrome in an Adult Patient without Ataxia and Telangiectasias 164
High frequency extradural motor cortex stimulation transiently improves axial symptoms in a patient with Parkinson's disease 163
Phenotypic variability of PINK1 expression: 12 Years' clinical follow-up of two Italian families 163
Epidemiological, Clinical, and Molecular Study of a Cohort of Italian Parkinson Disease Patients: Association with Glutathione-S-Transferase and DNA Repair Gene Polymorphisms 162
Blepharospasm with non-satisfactory response to treatment: Our experience with IncobotulinumtoxinA 162
Working on asymmetry in Parkinson's disease: randomized, controlled pilot study 162
Transcranial magnetic stimulation predicts functional recovery after botulinum toxin treatment in stroke patients 161
Clinical differences between botulinum neurotoxin type A and B 161
Clinical presentation and progression of sporadic and familial primary torsion dystonia in Italy. 160
Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson's disease. 159
Punding and computer addiction in Parkinson's disease 158
Levodopa effect on electromyographic activation patterns of tibialis anterior muscle during walking in Parkinson's disease 158
Bilateral high frequency subthalamic stimulation in Parkinson's disease: long-term neurological follow-up 158
Botulinum toxin injection for the treatment of chronic anal fissure: uni- and multivariate analysis of the factors that promote healing 158
Impact of disease duration and cardiovascular dysautonomia on hypertension in Parkinson's disease 157
An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients 156
DJ-1 modulates mitochondrial response to oxidative stress: clues from a novel diagnosis of PARK7 156
Botulinum toxin-B ultrasound-guided injections for sialorrhea in amytrophic lateral sclerosis and Parkinson's disease 155
Cocaine addiction: from habits to stereotypical-repetitive behaviors and punding 155
Liquid melevodopa versus standard levodopa in patients with Parkinson disease and small intestinal bacterial overgrowth 155
Cardiac autonomic nervous system evaluation in Parkinson disease and multisystem atrophy 154
Chronic motor cortex stimulation in patients with advanced Parkinson's disease and effects on striatal dopaminergic transmission as assessed by 123I-FP-CIT SPECT: a preliminary report 154
Functional Movement Disorders during COVID-19: Psychological Distress, Affective Temperament and Emotional Dysregulation 153
GPi-DBS in Huntington's disease: results on motor function and cognition in a 72-year-old case 153
Early DEtection of wEaring off in Parkinson disease: the DEEP study 152
Functional Movement Disorders during COVID-19: Psychological Distress, Affective Temperament and Emotional Dysregulation 151
Effects of deep brain stimulation of the subthalamic nucleus on patients with Parkinson's disease: a machine-learning voice analysis 151
Tremor in primary adult-onset dystonia: prevalence and associated clinical features 151
Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm 151
Totale 20.060
Categoria #
all - tutte 170.471
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 170.471


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.666 0 0 0 116 110 67 38 313 82 152 327 461
2022/20234.461 519 586 354 597 337 524 238 351 643 90 160 62
2023/20242.300 86 661 77 158 90 304 143 151 33 66 251 280
2024/20254.943 101 171 408 151 377 198 206 251 760 427 1.051 842
2025/202614.003 1.933 420 832 1.408 2.128 682 2.513 883 893 1.180 523 608
2026/20276.133 789 1.627 1.109 2.608 0 0 0 0 0 0 0 0
Totale 42.430